ALXO - ALX Oncology falls after releasing evorpacept study data in myelodysplastic syndromes

ALX Oncology (ALXO -23.3%) shares have lost more than a fifth to reach a 12-month low after the company released preliminary data for its lead asset evorpacept from a Phase 1/2 trial in combination with chemotherapy azacitidine in myelodysplastic syndromes (“MDS”). As of mid-July, the trial had enrolled 13 patients with newly diagnosed (“ND”) higher risk or relapsed/refractory (“R/R”) disease. The data from the abstract will be part of a poster presentation at the upcoming 63rd American Society of Hematology (“ASH”) Annual Meeting. Out of the five ND subjects evaluable for response (all had TP53 mutation), two subjects with cytogenetic response met the criteria for complete response (“CR”) following the date of the abstract, the company said. One subject each showed the best response of marrow complete response (“mCR”) with hematologic improvement (“HI”), stable disease (“SD”), and progressive disease (“PD”). Out of four R/R subjects who were not reliant on transfusion

For further details see:

ALX Oncology falls after releasing evorpacept study data in myelodysplastic syndromes